Oncogene-Directed Therapies

  • Janusz Rak

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Basic Concepts in Oncogene Research

    1. Front Matter
      Pages 1-1
    2. Susan J. Done, Jeremy A. Squire
      Pages 3-17
    3. Frank McCormick
      Pages 35-46
    4. Mark H. Kirschbaum, Mina D. Marmor, Yosef Yarden
      Pages 47-75
  3. The Functional Impact of Oncogene Expression on Cancer Cells—Therapeutic Implications

    1. Front Matter
      Pages 131-131
    2. Marcelo L. Rodriguez-Puebla, Adrian M. Senderowicz, Claudio J. Conti
      Pages 133-151
    3. Kirill Rosen, Jorge Filmus
      Pages 153-169
    4. Janusz Rak, Robert S. Kerbel
      Pages 171-218
    5. Ann F. Chambers, Hemanth J. Varghese
      Pages 219-228
    6. Senji Shirasawa, Takehiko Sasazuki
      Pages 229-243
    7. Michaela Herzig, Gerhard Christofori
      Pages 245-294
  4. Oncogenes as Targets for Anticancer Therapy in Vivo

    1. Front Matter
      Pages 295-295
    2. Michael E. O’Dwyer, Brian J. Druker
      Pages 297-311
    3. Gottfried E. Konecny, Jane Arboleda, Dennis J. Slamon, Mark Pegram
      Pages 331-351
    4. Gelareh Zadeh, Abhijit Guha
      Pages 363-382
    5. Giannoula Klement, Robert S. Kerbel
      Pages 383-408
    6. Eric J. Bernhard, Anjali K. Gupta, Elizabeth Cohen-Jonathan, Ruth J. Muschel, Stephen M. Hahn, W. Gillies McKenna
      Pages 409-432
    7. Samir N. Khleif, Joseph A. Lucci III
      Pages 433-452
    8. Finbarr E. Cotter, Dean A. Fennell
      Pages 453-468
  5. Back Matter
    Pages 469-486

About this book


In recent years an entirely new category of anticancer agents has entered the clinic. This class of drugs, the frontrunners of which are Herceptin and Gleevec, are no longer a product of the intuitive and largely empirical explorations that brought about traditional anticancer treatments like chemotherapy. Rather, these new agents have emerged directly from molecular analysis of various cancer-causing genes (oncogenes). In Oncogene-Directed Therapies, prominent investigators and clinicians, several of them pioneers in the field, summarize what is known about oncogenes and oncogenesis-in a balanced blend of fundamental science, basic research, experimental therapeutics, and early clinical experience-and describe how that knowledge can be used to treat the disease. The contributors explain how, why, and under what conditions certain proteins acquire the ability to transform eukaryotic cells, and detail the crucial biological consequences of this oncogenic transformation, particularly for cellular mitogenesis, survival, differentiation, migration, proteolysis, or angiogenic competence. Their articles thoroughly explicate the premises, principles, techniques, and approaches to oncogene targeting in various types of human cancer by using signal transduction inhibitors, immunological targeting methods, and antisense gene therapy. Also included is a review of the results of preclinical and clinical testing of some of today's most advanced therapeutic agents.
Unique in perspective and comprehensive in its coverage, Oncogene-Directed Therapies not only integrates for all those engaged in-or simply interested in the cutting-edge of-"the war on cancer" the many remarkable recent achievements in our molecular understanding and treatment of these diseases, but also clarifies what directions future research might optimally take, as well as what significant accomplishments might lie ahead.


angiogenesis cell gene therapy metastasis oncogene tumor tumorigenesis

Editors and affiliations

  • Janusz Rak
    • 1
  1. 1.Henderson Research Centre, Department of MedicineMcMaster UniversityHamiltonCanada

Bibliographic information